Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icodextrin peritoneal dialysis solution for volume status improvement in peritoneal dialysis patients
ChiCTR2200062379Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of icodextrin in end-stage kidney disease (ESKD) (2 arms), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoints: Volume status and Ultrafiltration volume. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
icodextrin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2200062379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062379.